How to evaluate combination therapy using interferon and nucleos(t)ide analogues

VernacularTitle:如何评价干扰素与核苷和核苷酸类药物的联合治疗
Author: Lu CHEN ¹ ; Qing XIE
Author Information

1. Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University Medical School, Shanghai 200025, China
Publication Type:Research Article
Keywords: hepatitis B, chronic; interferons; nucleosides; nucleotides; drug therapy, combination
From: Journal of Clinical Hepatology 2016;32(11):2050-2053
CountryChina
Language:Chinese
Abstract: Chronic hepatitis B is still one of the most important chronic diseases in China because of its high relevance to liver cirrhosis and hepatic cell cancer (HCC). Currently, interferon and nucleos(t)ide analogues are two main treatments for chronic hepatitis B, but they have advantages and disadvantages. More investigations are needed to explore better ways for treating this disease, and combination therapy might be one of the options. This article analyzes the advances in various combination therapies and points out views about the selection of combination therapies and patients.